The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“once weekly subcutaneous injection with semaglutide resulted in a marked and sustained weight loss of >15% in patients who are overweight or obese.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
Hyperkalemia in patients with heart failure: Incidence, prevalence, and management
Desai, A. S. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0037-1 · Cited by 59
Sex Differences in Heart Failure
Savarese, G., & D’Amario, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_32 · Cited by 63
Zaragoza‐Macias, E., Zaidi, A. N., Dendukuri, N., & Marelli, A. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1030 · Cited by 61
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2018 · Cited by 65
Self-citationQuiroz, R., Doros, G. D., Shaw, P., Liang, C., Gauthier, D. F., & Sam, F. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.014 · Cited by 59
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials
Ibrahim, N. E., Gaggin, H. K., Konstam, M. A., & Januzzi, J. L. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002528 · Cited by 59
Gevaert, A. B., Lemmens, K., Vrints, C. J., & Craenenbroeck, E. M. V. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4865756 · Cited by 60
Circulating microRNAs as novel biomarkers for heart failure
Chen, F., Yang, J., Li, Y., & Wang, H. (2017) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2017.10.002 · Cited by 59
Elgendy, I. Y., & Pepine, C. J. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.12.038 · Cited by 60
McMurray, J. J. V., & O’Connor, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1401231 · Cited by 64
Self-citationEdelmann, F., Wachter, R., Duvinage, A., Mueller, S., Fegers‐Wustrow, I., Schwarz, S., Christle, J. W., Pieske‐Kraigher, E., Seyfarth, M., Knapp, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03342-7 · Cited by 64
Heart Failure With Normal Left Ventricular Ejection Fraction: What is the Evidence?
Kindermann, M., Reil, J., Pieske, B. M., van Veldhuisen, D. J., & Böhm, M. (2008) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2008.12.003 · Cited by 59
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 60
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
Bikdeli, B., Punnanithinont, N., Akram, Y., Lee, I., Desai, N. R., Ross, J. S., & Krumholz, H. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005285 · Cited by 58
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Kumar, M. R., Park, K., & Lee, S. (2010) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201000592 · Cited by 58
Hamdani, N., Paulus, W. J., van Heerebeek, L., Borbély, A., Boontje, N. M., Zuidwijk, M. J., Bronzwaer, J. G. F., Simonides, W. S., Niessen, H. W. M., Stienen, G. J. M., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp189 · Cited by 57
Heart Failure with Preserved Ejection Fraction: Current Understandings and Challenges
Andersen, M. J., & Borlaug, B. A. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0501-8 · Cited by 59
Tereshchenko, L. G., Cygankiewicz, I., McNitt, S. A., Vázquez, R., Bayés‐Genís, A., Han, L., Sur, S., Couderc, J., Berger, R. D., Bayés‐Genís, A., et al. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.112.970541 · Cited by 60
Patel, K., Fonarow, G. C., Ekundayo, O. J., Aban, I., Kilgore, M. L., Love, T. E., Kitzman, D. W., Gheorghiade, M., Allman, R. M., & Ahmed, A. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.005 · Cited by 59
Evolving focus on diastolic dysfunction in patients with coronary artery disease
Ohara, T., & Little, W. C. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833f0438 · Cited by 57
Fukuta, H., Goto, T., Wakami, K., & Ohte, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.186 · Cited by 60
Renin–angiotensin system blockade for the risk of cancer and death
Shen, J. X., Huang, Y., Wang, M., Hong, X., Song, X.-N., Zou, X., Pan, Y.-H., Ling, W., Zhu, M., Zhang, X., et al. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316656679 · Cited by 59
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure
Feldman, T. E., Komtebedde, J., Burkhoff, D., Massaro, J. M., Maurer, M. S., Leon, M. B., Kaye, D. M., Silvestry, F. E., Cleland, J. G. F., Kitzman, D. W., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003025 · Cited by 59
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction
Tam, M., Lee, R., CASCINO, T. M., Konerman, M. C., & Hummel, S. L. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0709-2 · Cited by 57
Edelmann, F., Feuerstein, A., Gelbrich, G., Hasenfuss, G. P., Herrmann‐Lingen, C., Duvinage, A., Schwarz, S., Mende, M., Prettin, C., Trippel, T. D., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.862 · Cited by 58
Barison, A., Aimo, A., Ortalda, A., Todiere, G., Grigoratos, C., Passino, C., Camici, P. G., Aquaro, G. D., & Emdin, M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.043 · Cited by 58
Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
Slater, R. E., Strom, J. G., Methawasin, M., Liss, M., Gotthardt, M., Sweitzer, N. K., & Granzier, H. L. M. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201812259 · Cited by 60
ST2 in heart failure with preserved and reduced ejection fraction
Najjar, E., Faxén, U. L., Hage, C., Donal, E., Daubert, J., Linde, C. M., & Lund, L. H. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1583363 · Cited by 58
Renal Denervation to Treat Heart Failure
Sharp, T. E., & Lefer, D. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093431 · Cited by 56
Heart Failure With Preserved Ejection Fraction What is Known and Unknown
Yamamoto, K., Sakata, Y., Ohtani, T., Takeda, Y., & Mano, T. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1073 · Cited by 57
Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure
Dell’Italia, L. J. (2011) · Circulation Research · doi:10.1161/circresaha.110.238550 · Cited by 55
The anti-ageing molecule sirt1 mediates beneficial effects of cardiac rehabilitation
Russomanno, G., Corbi, G., Manzo, V., Ferrara, N., Rengo, G., Puca, A. A., Latte, S., Carrizzo, A., Calabrese, M. C., Andriantsitohaina, R., et al. (2017) · Immunity & Ageing · doi:10.1186/s12979-017-0088-1 · Cited by 57
VersorgungsLeitlinie, N. (2011) · Cited by 58
d’Almeida, K. S. M., Rabelo, E. R., Souza, G. C., Trojahn, M. M., Barilli, S. L. S., Aliti, G. B., Rohde, L. E. P., Biolo, A., & Neto, L. B. D. S. (2018) · Nutrition · doi:10.1016/j.nut.2018.02.007 · Cited by 56
Diastolic Dysfunction as a Link Between Hypertension and Heart Failure
Verma, A., & Solomon, S. D. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.013 · Cited by 58
Solal, A. C., Leurs, I., Assyag, P., Beauvais, F., Clerson, P., Contre, C., Thébaut, J.-F., & Genoun, M. (2012) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2012.04.003 · Cited by 56
Kwon, B., Kim, D., Jang, S.-W., Yoo, K., Moon, K., Shim, B. J., Ahn, S., Cho, E.-J., Rho, T., & Kim, J. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq157 · Cited by 56
Butler, J., Ezekowitz, J. A., Collins, S. P., Givertz, M. M., Teerlink, J. R., Walsh, M. N., Albert, N. M., Canary, C. A. W., Carson, P. E., Colvin, M. M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.02.005 · Cited by 58
Self-citationHeart failure with preserved ejection fraction
Harper, A. R., Patel, H. C., & Lyon, A. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-s24 · Cited by 56
Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis
Chaugai, S., Meng, W. Y., & Sepehry, A. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415619490 · Cited by 56
Abdul‐Rahim, A. H., Perez, A.-C., Macisaac, R. L., Jhund, P. S., Claggett, B. L., Carson, P. E., Michel Komajda, N., McKelvie, R. S., Zile, M. R., Swedberg, K. B., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw509 · Cited by 54
Self-citationTrial, J., Entman, M. L., & Cieslik, K. A. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.017 · Cited by 54
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 59
NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
Teuber, J. P., Essandoh, K., Hummel, S. L., Madamanchi, N. R., & Brody, M. J. (2022) · Antioxidants · doi:10.3390/antiox11091822 · Cited by 55
Kondo, T., Dewan, P., Anand, I. S., Desai, A. S., Packer, M., Zile, M. R., Pfeffer, M. A., Solomon, S. D., Abraham, W. T., Shah, S. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063642 · Cited by 54
Self-citationTsutsui, H., Tsuchihashi‐Makaya, M., & Kinugawa, S. (2009) · Journal of Cardiology · doi:10.1016/j.jjcc.2009.09.003 · Cited by 53
Cardiovascular Disease in the Elderly
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.003 · Cited by 55
Improving outcomes in heart failure: a personal perspective
McMurray, J. J. V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv565 · Cited by 53
Self-citationPharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
Zafeiropoulos, S., Farmakis, I. T., Milioglou, I., Doundoulakis, I., Gorodeski, E. Z., Konstantinides, S., Cooper, L. B., Zanos, S. P., Stavrakis, S., Giamouzis, G., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.014 · Cited by 58
Diagnosis and Management of Left Ventricular Diastolic Dysfunction in the Hypertensive Patient
Galderisi, M. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.235 · Cited by 52
Kurrelmeyer, K. M., Ashton, Y. P., Xu, J., Nagueh, S. F., Torre‐Amione, G., & Deswal, A. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.05.010 · Cited by 52
Niizuma, S., Iwanaga, Y., Yahata, T., Tamaki, Y., Goto, Y., Nakahama, H., & Miyazaki, S. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.121236 · Cited by 52
Fukuta, H., Goto, T., Wakami, K., & Ohte, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.239 · Cited by 52
Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review
Holubarsch, C., Colucci, W. S., & Eha, J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0249-9 · Cited by 52
Lewis, E. F., Claggett, B. L., Shah, A. M., Liu, J., Shah, S. J., Anand, I. S., O’Meara, E., Sweitzer, N. K., Rouleau, J. L., Fang, J. C.-T., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004457 · Cited by 52
Plitt, G. D., Spring, J. T., Moulton, M. J., & Agrawal, D. K. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497485 · Cited by 52
Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
Budde, H., Hassoun, R., Mügge, A., Kov́acs, Á., & Hamdani, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.928232 · Cited by 56
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
McDowell, K., Kondo, T., Talebi, A., Teh, K., Bachus, E., de Boer, R. A., Campbell, R. T., Claggett, B. L., Desai, A. S., Docherty, K. F., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0284 · Cited by 51
Self-citationHuang, G., Xu, J., Liu, J., He, Y., Nie, X.-L., Li, Q., Hu, Y., Zhao, S.-Q., Wang, M., Zhang, W., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02460.x · Cited by 52
Cardiac Remodelling and Myocardial Recovery: Lost in Translation?
Mann, D. L., Bogaev, R. C., & Buckberg, G. D. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq113 · Cited by 51
Ennezat, P. V., Maréchaux, S., Pîbarot, P., & Jemtel, T. H. L. (2013) · Cardiology · doi:10.1159/000350356 · Cited by 51
Ostrominski, J. W., Claggett, B. L., Miao, Z. M., Causland, F. R. M., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.005 · Cited by 56
Self-citationUeda, T., Kawakami, R., Nishida, T., Onoue, K., Soeda, T., Okayama, S., Takeda, Y., Watanabe, M., Kawata, H., Uemura, S., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0425 · Cited by 50
Maurer, M. S., Teruya, S. L., Chakraborty, B., Helmke, S. T., & MANCINI, D. M. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.969717 · Cited by 50
Donal, E., Lund, L. H., Oger, E., Hage, C., Persson, H., Reynaud, A. J., Ennezat, P., Bauer, F., Sportouch, C., Drouet, É., et al. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.11.002 · Cited by 53
Marume, K., Takashio, S., Nagai, T., Tsujita, K., Saito, Y., Yoshikawa, T., & Anzai, T. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0639 · Cited by 52
Rush, C. J., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy407 · Cited by 52
Self-citationExercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
Litwin, S. E., Komtebedde, J., Hu, M., Burkhoff, D., Hasenfuss, G. P., Borlaug, B. A., Solomon, S. D., Zile, M. R., Mohan, R. C., Khawash, R., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.030 · Cited by 51
Self-citationNeuen, B. L., Vaduganathan, M., Claggett, B. L., Beldhuis, I. E., Myhre, P. L., Desai, A. S., Skali, H., Causland, F. R. M., McGrath, M. M., Anand, I. S., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.009 · Cited by 57
Self-citationNon-sirtuin histone deacetylases in the control of cardiac aging
Ferguson, B. S., & McKinsey, T. A. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.03.010 · Cited by 49
Kristensen, S. L., Jhund, P. S., Køber, L., Preiss, D., KJEKSHUS, J. K., McKelvie, R. S., Zile, M. R., Anand, I. S., Wikstrand, J., Wedel, H., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.211 · Cited by 49
Self-citationAn overview of hypertension and cardiac involvement in Asia: Focus on heart failure
Soenarta, A. A., Buranakitjaroen, P., Chia, Y. C., Chen, C., Nailes, J. M., Hoshide, S., Minh, H. V., Park, S., Shin, J., Siddique, S., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13753 · Cited by 54
Novel estrogen receptor coregulators and signaling molecules in human diseases
Barnes, C. J., Vadlamudi, R. K., & Kumar, R. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3222-5 · Cited by 47
Colvin, M. M., Sweitzer, N. K., Albert, N. M., Krishnamani, R., Rich, M. W., Stough, W. G., Walsh, M. N., Canary, C. A. W., Allen, L. A., Bonnell, M. R., et al. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.05.013 · Cited by 50
Self-citationPrevention, Diagnosis, and Treatment of Hypertensive Heart Disease
Georgiopoulou, V. V., Kalogeropoulos, A. P., Raggi, P., & Butler, J. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.07.005 · Cited by 50
Oghlakian, G. O., Sipahi, İ., & Fang, J. C.-T. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0841 · Cited by 48
Female Heart Health: Is GPER the Missing Link?
Groban, L., Tran, Q., Ferrario, C. M., Sun, X., Cheng, C. P., Kitzman, D. W., Wang, H., & Lindsey, S. H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00919 · Cited by 49
Vaduganathan, M., Jhund, P. S., Claggett, B. L., Packer, M., Widimsky, J., Jr., Seferovic, P. M., Rizkala, A. R., Lefkowitz, M. P., Shi, V. C., McMurray, J. J. V., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa184 · Cited by 48
Self-citationSuna, S., Hikoso, S., Yamada, T., Uematsu, M., Yasumura, Y., Nakagawa, A., Takeda, T., Kojima, T., Kida, H., Oeun, B., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038294 · Cited by 49
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Gandhi, P. U., Chow, S. L., Rector, T. S., Krum, H., Gaggin, H. K., McMurray, J. J. V., Zile, M. R., Michel Komajda, N., McKelvie, R. S., Carson, P. E., et al. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.06.006 · Cited by 47
Self-citationEchocardiographic Predictors of Sudden Cardiac Death
Konety, S., Koene, R. J., Norby, F. L., Wilsdon, T., Alonso, Á., Siscovick, D. S., Sotoodehnia, N., Gottdiener, J. S., Fox, E. R., Chen, L. Y., et al. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.004431 · Cited by 46
Savarese, G., Hage, C., Orsini, N., Dahlström, U., Filardi, P. P., Rosano, G. M. C., & Lund, L. H. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003105 · Cited by 47
Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy
Hinze, F., Dieterich, C., Radke, M. H., Granzier, H. L. M., & Gotthardt, M. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1483-3 · Cited by 45
Wilck, N., Markó, L., Balogh, A., Kräker, K., Herse, F., Bartolomaeus, H., Szijártó, I. A., Gollasch, M., Reichhart, N., Strauß, O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96006 · Cited by 47
Treatment of Heart Failure with Preserved Ejection Fraction
Ilieșiu, A. M., & Hodorogea, A. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_149 · Cited by 51
Cho, J. H., Zhang, R., Aynaszyan, S., Holm, K., Goldhaber, J. I., Marbán, E., & Cingolani, E. (2018) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.118.006452 · Cited by 47
Sudden cardiac death risk prediction in heart failure with preserved ejection fraction
Adabağ, S., & Langsetmo, L. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.12.009 · Cited by 47
Setoguchi, M., Hashimoto, Y., Sasaoka, T., Ashikaga, T., & Isobe, M. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0532-5 · Cited by 46
Al‐Mohammad, A., & Mant, J. (2011) · Heart · doi:10.1136/hrt.2010.214999 · Cited by 46
Kyoto Congestive Heart Failure (KCHF) Study: Rationale and Design
Yamamoto, E., Kato, T., Ozasa, N., Yaku, H., Inuzuka, Y., Tamaki, Y., Kitai, T., Morimoto, T., Taniguchi, R., Iguchi, M., et al. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12138 · Cited by 46
Selvaraj, S., Claggett, B. L., Shah, S. J., Anand, I. S., Rouleau, J. L., Desai, A. S., Lewis, E. F., Pitt, B., Sweitzer, N. K., Pfeffer, M. A., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1060 · Cited by 48
Rouhana, S., Farah, C., Roy, J., Finan, A., de Araújo, G. R., Bideaux, P., Scheuermann, V., Saliba, Y., Reboul, C., Cazorla, O., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.005 · Cited by 52
Myocardial reverse remodeling: how far can we rewind?
Gonçalves‐Rodrigues, P., Leite-Moreira, A. F., & Falcão‐Pires, I. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00696.2015 · Cited by 48
Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction
Tona, F., Montisci, R., Iop, L., & Civieri, G. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2021.01.277 · Cited by 48
Cardiorenal Anemia Syndrome as a Prognosticator for Death in Heart Failure
Lu, K. J., Kearney, L. G., Hare, D. L., Ord, M., Toia, D., Jones, E. F., Burrell, L. M., & Srivastava, P. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.049 · Cited by 44
Morris, D. A., Pérez, A. V., Blaschke, F., Eichstädt, H. W., Özcelik, C., & Haverkamp, W. (2012) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jes042 · Cited by 45
Mega clinical trials which have shaped the RAS intervention clinical practice
Düsing, R. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716644131 · Cited by 44
Metadata
- Authors
- Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., & Ptaszynska, A.
- Affiliations
- San Francisco VA Medical Center (US)
- Georgetown University (US)
- University of Glasgow (GB)
- Hamilton Health Sciences (CA)
- Medical University of South Carolina (US)
- University of Wisconsin–Madison (US)
- Bristol-Myers Squibb (United States) (US)
- Sanofi (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2456-2467
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068519950
- Cited by
- 1,960
- References
- 37
- Citations by year
- 2026: 61 · 2025: 72 · 2024: 92 · 2023: 94 · 2022: 128 · 2021: 120 · 2020: 123 · 2019: 118 · 2018: 117 · 2017: 138 · 2016: 105 · 2015: 127 · 2014: 119 · 2013: 122 · 2012: 109
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- irbesartan, heart failure with preserved ejection fraction, angiotensin receptor blockers, cardiovascular mortality, cardiovascular hospitalization, heart failure hospitalization, quality of life, elderly patients
- MeSH terms
- Irbesartan, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiovascular Diseases, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Tetrazoles, Proportional Hazards Models, Treatment Failure, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
